Sino Biopharmaceutical (HKSE:01177) Accounts Payable & Accrued Expense : HK$4,806 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Accounts Payable & Accrued Expense?

Sino Biopharmaceutical's quarterly accounts payable & accrued expense increased from Dec. 2022 (HK$4,348 Mil) to Jun. 2023 (HK$17,859 Mil) but then declined from Jun. 2023 (HK$17,859 Mil) to Dec. 2023 (HK$4,806 Mil).

Sino Biopharmaceutical's annual accounts payable & accrued expense declined from Dec. 2021 (HK$4,431 Mil) to Dec. 2022 (HK$4,348 Mil) but then increased from Dec. 2022 (HK$4,348 Mil) to Dec. 2023 (HK$4,806 Mil).

Sino Biopharmaceutical Accounts Payable & Accrued Expense Historical Data

The historical data trend for Sino Biopharmaceutical's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Accounts Payable & Accrued Expense Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

4,214.39

6,134.42

4,430.64

4,348.49

4,806.13

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															4,430.64	14,101.47	4,348.49	17,858.61	4,806.13

Sino Biopharmaceutical Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Sino Biopharmaceutical (HKSE:01177) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Executives

Tse Eric S Y	2101 Beneficial owner
Tse Ping	2101 Beneficial owner
Cheng Cheung Ling	2101 Beneficial owner
True Merit Global Limited	2101 Beneficial owner
Tse Theresa Y Y	2101 Beneficial owner
Thousand Eagles Limited	2101 Beneficial owner
France Investment (china 1) Group Limited	2101 Beneficial owner
Remarkable Industries Limited	2101 Beneficial owner
Validated Profits Limited	2101 Beneficial owner

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines